Category: Uncategorised

19 May 2019

4Dx Presents First Human Scan Data From XV Technology Clinical Trials

Andreas Fouras, PhD, (founder and CEO of 4Dx) presented this week the first release of the highly anticipated results from 4Dx’s clinical trials at the American Thoracic Society (ATS) 2019 International Conference in Dallas, TX,

4Dx opened Day 1 of the 3-day conference with a newly-designed booth dedicated to showcasing the first of many 4-dimensional human data scans obtained from clinical trials.  Video walls, touchscreen TVs and a high-tech hologram attraction served as focal points for the booth to display XV Technology’s heatmap-coded, single slice ventilation distribution contour maps, identifying normal and abnormal lung function.

Additionally, Andreas was invited to speak at the Respiratory Innovation Summit that took place two days before the start of ATS.  Andreas’ 6-minute presentation included early stage validation data illustrating the efficacy of XV Technology in detecting regional lung function defects in human subjects, as well as quantitative analysis graphics that highlight lung ventilation throughout the course of a full breath.

4Dx is currently presenting at their booth (#3543)  running through May 21.

19 Feb 2017


Melbourne, Australia, 20 February, 2017: Dr. Andreas Fouras, founder and CEO of medical technology company 4Dx Limited, will present preliminary clinical data at the prestigious World Lung Imaging Workshop on the 2nd of March at the University of Pennsylvania.

The software technology developed by 4Dx provides richer information, allowing for earlier detection of respiratory related disease.  Dr. Fouras, who founded the company in 2012, says that “presenting the first 4Dx in human clinical data is a great milestone for the company and we are excited to share these results to many of the world’s leading lung imaging experts at such a prestigious event”.

4Dx technology enables clinicians to capture images that effectively visualise and quantify motion of airflow at high resolution within the breathing lungs.  Currently more than 162 million respiratory diagnostic procedures are performed each year, at a cost of $25 billion per annum.

4Dx limited currently has a range of formal engagements with some of the leading institutions across the United States and is moving rapidly towards a commercial product in the United States by 2018.

21 Sep 2016

Appointment of General Manager – Notting Hill Devices

4Dx is excited to announce that Paul Cooke will be taking on the role of General Manager of 4Dx’s specialist hardware subsidiary, Notting Hill Devices. As Paul moves into this role, he will be stepping aside from his role as Non-Executive Director, effective 1st September. During his tenure as Non-Executive Director, Paul played a key role in lifting 4Dx’s profile during our recent capital raising endeavours.


02 Sep 2016

Andreas Fouras, CEO of 4Dx, says backing bright people is a bright idea

Andreas Fouras, Founder and CEO of 4Dx, spoke with Nature Index on the recent call from the National Health and Medical Research Council (NHMRC) for public consultation on the structural review of their grant program.

m1Following criticism that current funding models are failing to support researchers across all stages of their careers, the NHMRC have opened the debate around three proposed alternative models to review research grant submissions: two based largely on funding people, as individuals or teams; and one that supports ideas.

Andreas joins the camp to support funding people, stating that the disadvantage of funding projects or ideas is that review panels struggle to evaluate projects that draw on multidisciplinary expertise, “there are no panels for research identified as belonging to ‘other’ fields, ” he says.

To read the full article click here.



01 Sep 2016

4Dx retail round closes with full subscription

Scan-room-with-4dx-reportWe are pleased to announce that our recent retail offer of shares is now fully subscribed after successfully raising AU$500,000.

It is very encouraging to gain backing so enthusiastically from retail investors committed to seeing our technology come to market as fast as possible.

These funds take us a step closer to commercialising our technology through ongoing clinical validation and expansion of our US operation, where Founder and CEO, Andreas Fouras, is now based.

We would like to thank all of our investors for their ongoing support and will continue to update you with news as we reach significant milestones.

To find out about future opportunities, please register your interest here.

25 Aug 2016 interview 4Dx on their advanced visualization tool being used for imaging lung disease

4Dx was interviewed by, an influential community site for radiologists and related professionals in the medical imaging industry.

In the article “Advanced visualization tool assesses lung disease”, Eric Barnes interviewed the 4Dx team on the new technique they have developed that combines fluoroscopy and advanced visualization to generate high-resolution images of the motion and airflow of lung tissue.


“The patients breathe under fluoro and we can record the motion of the tissues, and from that we can quantify a number of things, like ventilation,” said Andreas Fouras, CEO and Founder of 4Dx.

4Dx uses software to segment and track the bronchial tree and estimate airflow inside that part of the body. The team explained that, assuming air inside the lung and lung tissue is incompressible, the calculated lung expansion directly represents airflow into and out of the lung regions.

Asked how the technology will be used, Andreas explained that they foresee a number of clinical applications.

“Depending on the nature of the disease, it may be easier to see the disease through an image of the ventilation, or it may be easier to see it on the airways themselves where you can see the airflow going through,” he explained. “It primarily depends on whether the disease is restrictive [affecting the tissues] or obstructive [affecting the airways].”


4Dx has tested the technology in animal studies and has started performing human trials with leading Australian and US hospitals.

Andreas believes the images to be very powerful for diagnosis of common lung disease, and, more importantly, for the monitoring and follow-up of a patient as a disease progresses, or as a patient undergoes treatment.

To view the original article “Advanced visualization tool assesses lung disease”, by Eric Barnes is available to members at

24 Aug 2016

4Dx’s CEO talks to the Australian Financial Review about how our culture is stifling innovation

Light BulbThe AFR cover insights from last weeks meeting of 400 of the top people in the innovation sector, where Andreas Fouras, CEO of 4Dx, highlighted one of the biggest problems Australia faces as it seeks to become high tech nation.

Contrary to the risk taking the government would lead us to believe is encouraged as a nation, when researchers leave academia and attempt to commercialise their research, if it doesn’t work out, they are rarely taken back.

Taking a leap of faith to quit a career to go and build a startup is daunting enough, but as noted by Andreas, as an academic, you want to be sure.

Andreas is so convinced of the merit of his research he sold his house, quit his job and relocated his entire family to the US.
Click here to read the full article.

18 Aug 2016

4Dx’s Andreas Fouras speaks alongside Australia’s leading academics and experts at the AFR Innovation Summit 2016

Andreas Fouras, CEO of 4Dx, yesterday joined some of  Australias leading scientists and academics at The Australian Financial Reviews  Innovation Summit to discuss Australia’s need to change its attitude toward entrepreneurial failure to protect the economy from missing out on the benefits created by risk takers.

Dr Finkel, Australia’s chief scientist, who was also speaking, highlighted that Australia’s start-up ecosystem will find success with the right attitude, investments and policies. This, he says, could maximise Australia’s potential to punch well above its weight.Andreas Presenting

Andreas added during his round table ‘Deconstructing successful commercialization: Lessons from the coalface’ that a key success factor for innovation was that it is important to have more mobility between universities and business and with other research organisations such as the CSIRO.

The article was published in today’s AFR on Page 2 or click here to read the full article online.